Bibliography
- Löscher W , PotschkaH. Blood–brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx2(1), 86–98 (2005).
- Tamai I , TsujiA. Transporter-mediated permeation of drugs across the blood–brain barrier. J. Pharm. Sci.89(11), 1371–1388 (2000).
- Reese TS , KarnovskyMJ. Fine structural localization of a blood–brain barrier to exogenous peroxidase. J. Cell Biol.34(1), 207–217 (1967).
- Schinkel AH . P-glycoprotein, a gatekeeper in the blood–brain barrier. Adv. Drug. Deliv. Rev.36(2–3), 179–194 (1999).
- Zlokovic BV . The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron57(2), 178–201 (2008).
- Ronaldson PT , DavisTP. Targeting molecular mechanisms of blood–brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery Ther. Deliv. DOI: 10.4155/TDE.11.67 (2011) (In press).
- Selkoe DJ . Alzheimer‘s disease: genes, proteins, and therapy. Physiol. Rev.81(2), 741–766 (2001).
- Zlokovic BV . Neurovascular mechanisms of Alzheimer‘s neurodegeneration. Trends Neurosci.28(4), 202–208 (2005).
- Deane R , WuZ, SagareAet al. LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron 43(3), 333–344 (2004).
- Lam FC , LiuR, LuPet al. β-amyloid efflux mediated by p-glycoprotein. J. Neurochem. 76(4), 1121–1128 (2001).
- Kuhnke D , JedlitschkyG, GrubeMet al. MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer‘s amyloid-β peptides: implications for the mechanisms of Aβ clearance at the blood–brain barrier. Brain Pathol. 17(4), 347–353 (2007).
- Cirrito JR , DeaneR, FaganAMet al. P-glycoprotein deficiency at the blood–brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J. Clin. Invest. 115(11), 3285–3290 (2005).
- Hartz AM , MillerDS, BauerB. Restoring blood–brain barrier P-glycoprotein reduces brain Aβ in a mouse model of Alzheimer‘s disease. Mol. Pharmacol.77(5), 715–723 (2010).
- Tai LM , LoughlinAJ, MaleDK, RomeroIA. P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-β. J. Cereb. Blood Flow Metab.29(6), 1079–1083 (2009).
- Candela P , GosseletF, Saint-PolJet al. Apical-to-basolateral transport of amyloid-β peptides through blood–brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J. Alzheimer Dis. 22(3), 849–859 (2010).
- Ito S , OhtsukiS, TerasakiT. Functional characterization of the brain-to-blood efflux clearance of human amyloid-β peptide (1–40) across the rat blood–brain barrier. Neurosci. Res.56(3), 246–242 (2006).
- Yamada K , HashimotoT, YabukiCet al. The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid β peptides in an in vitro model of the blood–brain barrier cells. J. Biol. Chem. 283(50), 34554–34562 (2008).
- Nazer B , HongS, SelkoeDJ. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-β peptide in a blood–brain barrier in vitro model. Neurobiol. Dis.30(1), 94–102 (2008).
- Vogelgesang S , CascorbiI, SchroederEet al. Deposition of Alzheimer‘s β-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12(7), 535–541 (2002).
- Vogelgesang S , WarzokRW, CascorbiIet al. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer‘s disease. Curr. Alzheimer Res. 1(2), 121–125 (2004).
- Wijesuriya HC , BullockJY, FaullRL, HladkySB, BarrandMA. ABC efflux transporters in brain vasculature of Alzheimer‘s subjects. Brain Res.1358, 228–238 (2010).
- Jeynes B , ProviasJ. An investigation into the role of P-glycoprotein in Alzheimer‘s disease lesion pathogenesis. Neurosci. Lett.487(3), 389–393 (2011).
- Rizzi M , CacciaS, GuisoGet al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J. Neurosci. 22(14), 5833–5839 (2002).
- Seelbach MJ , BrooksTA, EgletonRD, DavisTP. Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein. J. Neurochem.102(5), 1677–1690 (2007).
- Bartels AL , KortekaasR, BartJet al. Blood–brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol. Aging 30(11), 1818–1824 (2009).
- Bartels AL , WillemsenAT, KortekaasRet al. Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson‘s disease, PSP and MSA. J. Neural. Transm. 115(7), 1001–1009 (2008).
- Salkeni MA , LynchJL, Otamis-PriceT, BanksWA. Lipopolysaccharide impairs blood–brain barrier P-glycoprotein function in mice through prostaglandin- and nitric oxide-independent pathways. J. Neuroimmune Pharmacol.4(2), 276–282 (2009).
- Lubberink M , Van Assema D, Hendrikse NH, Schuit R, Lammertsma A, Van Berckel B. Decreased P-glycoprotein function at the blood–brain barrier in patients with Alzheimer‘s disease as shown by (R)-[11C]verapamil and PET. J. Nucl. Med.51(Suppl. 2), 443 (2010).
- Nicolazzo JA , MehtaDC. Transport of drugs across the blood–brain barrier in Alzheimer‘s disease. Ther. Deliv.1(4), 595–611 (2010).